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Abstract
Background: Asthma as a chronic health condition can be controlled when in addition to clinical care, adequate
education and support is provided to enhance self-management. Like many other chronic health conditions
improved self-management positively impacts the health-related quality of life (HRQoL). It can therefore be said
that a well-structured pharmaceutical care delivery that addresses the issues related to patient education and
support towards self-management stands a good chance of positively impacting asthma control.
This study evaluated the impact of a structured pharmaceutical care delivery on asthma control.
Methods: A prospective pre-/post- intervention study of a single cohort of 77 adult out-patients visiting specialist asthma
clinics in Ghana were assessed for HRQoL and peak expiratory flow rates (PEFR) one month after pharmaceutical care
intervention. Pharmaceutical care intervention covered education on the health condition, pharmacotherapy and self-
management issues as well as correction of inhaler-use technique, where necessary and when to urgently seek medical
care. The mean difference of the HRQoL and PEFR values were subjected to paired samples t-test analysis.
Results: Delivery of a structured pharmaceutical care led to a significant improvement in asthma specific quality of life
and PEFR. The mean paired difference of the HRQoL for a cohort of patients with asthma post- pharmaceutical care
intervention was 0.697(95% CI: 0.490 - 0.900) at t = 6.85 (p < 0.05). The mean paired difference for PEFR post intervention
was 17.533 (95% CI: 2.876 - 32.190) at t = 2.384 (p = 0.02).
Conclusion: This study identified important challenges with both the pharmacologic and the non-pharmacologic
management of adult asthma patients. Inadequate inhaler-use skills, widespread occurrence of preventable adverse
events and irregular use of preventer medicines were prevalent among patients. At one month after pharmaceutical care
intervention, patients with asthma in a cohort follow-up study showed significant improvements with regard to asthma-
specific quality of life, peak flow rates and knowledge
Trial registration: GHS-ERC: 08/9/11 of October 19, 2011.
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Background
In the year 2012, non-communicable diseases (NCDs)
were responsible for 38 million (68%) of the 56 million
global deaths as reported by the World Health
Organization (WHO) [1]. This report classified more than
40% of these deaths as premature under the age of
70 years. In Ghana NCDs were reported to have
accounted for 42% of total deaths of which about 2% were
associated to chronic respiratory diseases [1].
Asthma is a chronic respiratory disease with a rising
prevalence within the African region [2]. The Asthma
Burden report has indicated that some 50 million cases
of asthma are believed to prevail in Africa, with South
Africa alone having a prevalence rate of about 8.1% [2].
The findings of the International Study of Asthma and
Allergies in Childhood (ISAAC) report (2007) indicated
that the international difference in asthma symptom
prevalence has generally reduced, particularly in the 13–
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14 year age group and with decreases in prevalence in
Western Europe [3]. The results however, indicated in-
creases in prevalence in regions where prevalence was
previously low, such as in Africa and parts of Asia [3].
These indications of growing trends of asthma in Africa
were corroborated by Adeloye and colleagues [4] who
also estimated a rising asthma prevalence in Africa,to be
in the region of about 74 million to 119.3 million over
the past two decades (1990–2010). The incidence rate of
asthma in Ghana has however been estimated at 1.5/
1000 per year by the WHO [5].
Notwithstanding these levels of occurrence, most
health care systems are still organised around the acute
care model which does not meet the management needs
of patients with NCDs. The WHO-Innovative Care for
Chronic Conditions report (2002) has suggested that
supported self-management with regular follow-ups in
addition to effective treatments improves the outcomes
for chronically ill patients [6].
The main stay for asthma management that conforms
to this innovative care for NCDs is the continuous mon-
itoring of the patient for asthma control and therapy ad-
justments that are intended to minimize the symptoms
regardless of the severity of the condition [7, 8]. Studies
performed by Juniper and colleagues [9] have shown
close correlation between the values of the Health-
Related Quality of Life (HRQoL) of asthma patients and
the levels of their asthma control. On the basis of these
advances, various studies on asthma have used the
HRQoL to assess the impact of interventions.
These trials, and especially those related to determin-
ation of effect of patient education by pharmacists on
the outcomes of the disease have shown mixed results
[10–16]. Some of these studies have indicated improve-
ments in patient symptom scores [15], quality of life
measurements, [15, 17–19] asthma severity [15, 17] and
PFR [15, 17, 19]. The extent of the interventions was
broad and may have introduced some bias into these
studies. Various levels of bias could have been intro-
duced from the drug therapy interventions and PEFR as-
sessments and interpretations from the skills of the
pharmacists at the multiple sites for the interventions.
Some studies used only asthma severity [15] as primary
outcomes measure, while others investigated only some
aspects of asthma control [17]. Some of the studies pro-
tracted beyond 3 months, [15, 17–19] but did not rea-
sonably resolve the issues of sustainability in such a
chronic disease that is influenced by numerous intrinsic
and extrinsic factors. The GINA [7] recommendations
with regards to continuous monitoring and adjustments
of therapy towards asthma control should apply here for
pharmacy interventions as well.
Furthermore most of these studies used case–control
methods in community settings where the participants
in the “case” group cannot be totally isolated from those
in the “control” group of the study. In cases where edu-
cation impacts outcome, then it must be ensured that
there is no exchange between the “case” and “control”
participants.
It is for these reasons that this researchers opted for a
single cohort study and fewer sites to allow only two
trained pharmacists to undertake the interventions. The
interventions were also only focused on patient under-
standing of the disease condition, the medications and
the appropriate use of the prescribed medications. The
study employed the use of the HRQoL instrument as the
primary outcome measure of asthma control. Secondary
outcomes were the measurements of PEFR and inhal-
ation technique scores. This cohort trial was organised
to study the hypothesis that provision of organised
pharmaceutical care that focussed on patient education
on prescribed medications, would improve asthma con-
trol in adult patients.
Methods
Design
A prospective pre-/post- intervention study of a single
cohort of adult out-patients visiting specialist asthma
clinics in Ghana were assessed for HRQoL and peak ex-
piratory flow rates (PEFR) at baseline and one month
after pharmaceutical care intervention. Pharmaceutical
care intervention covered education on the health condi-
tion, pharmacotherapy and self-management issues as
well as correction of inhaler-use technique, where neces-
sary and self-referral for early unscheduled review for
worsening asthma condition. The mean differences in
HRQoL and PEFR values were subjected to a paired
samples t-test analysis.
Setting
Four out-patient clinical sites were used in the study.
Two were teaching hospitals that managed referral cases
from various health institutions and run specialist
asthma clinics once a week. The two other hospitals
were not teaching hospitals, but one runs specialist
asthma clinics. All the clinical sites were located within
the southern and middle belts of Ghana.
Sample-size estimation
Assuming a mean HRQoL difference size of 0.5 (the
minimum important difference of clinical significance)
[20] and a standard deviation of HRQOL score of 0.8
from previous studies in the literature, the calculated
standardized effect size (the mean difference / standard
deviation) was estimated to be approximately 0.6. To es-
timate the sample size to test the hypothesis, a power (β)
of 0.9 and the level (two-sided) of statistical significance
(α) of 0.05 were set. Using these settings, the estimated
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sample size required for the cohort, when using the
paired samples t-test to compare means of continuous
variables to determine the minimum important differ-
ence of 0.5 was 60 patients. A convenience sample of 92
patients was used recruited for the study.
Data collection instrument
Two sets of data collection instruments were used in this
study. The Model Pharmaceutical Care Instrument was
used to collect data on participant demographics, medica-
tion profile, inhaler-use technique, perceived adverse
medication events, peak expiratory flow rates symptoms
and environmental trigger factors. This was used to guide
participant education. Review of this data identified care-
needs of every participant in the study. Care needs ad-
dressed included: understanding of disease condition and
the role of the various medications; inhaler-use technique;
issues of medication adherence; availability of medications;
management of trigger-factors; management of adverse
events, and peak flow meter assessment of lung function.
The standard Asthma Quality of Life Questionnaire
(AQLQ(S)) and the Peak Expiratory Flow Meter (“Air-
zone” flow meter by Clenment Clarke International)
were used to assess participant HRQoL and lung func-
tion pre and post pharmaceutical care intervention..It
was adopted to measure the functional problems (phys-
ical, emotional, social and occupational) that are most
troublesome to adults (17–70 years) with asthma. The
AQLQ(S) is an asthma-specific instrument that had been
validated in clinical trials [21]. The AQLQ(S) contains
32 questions (items) comprising four domains: Activity
Limitations, Asthma Symptoms, Emotional Function
and Environmental Exposure. Each item was scored
based on a 2-week recall of activities on a 7-point Likert
scale with Point 1 indicating severe impairment and
point 7 indicating no impairment. The overall score for
HRQoL was the mean score of the 32 items.
A change in mean overall or domain score of 0.5 had
been shown to represent the smallest change of import-
ance to the patient (the “minimal important difference”),
and a change in score of 1.0 represents a moderate
change [20]. However, a maximum overall AQLQ(S)
score of 7 represents no impairment in QOL due to
asthma, and scores approaching 7 imply a minimal im-
pact of asthma on QOL.
Ethical clearance
Having obtained an ethical clearance from the Ghana
Health Service (GHS-ECH: 08/9/11) and participant con-
sent, ninety two (92) adults with symptomatic asthma,
without other active co-morbidities, who visited the out-
patient clinic, were recruited into the study.
Data collection and intervention
Asthma patients attending regular clinical review in 4
selected hospitals located in the middle and southern
belts of Ghana were recruited into the study. Eligibility
for participation was limited to patients aged 17–70
years who have been medically diagnosed with asthma
and had no active co-morbidities. Excluded in the study
were patients whose medications were changed in
their previous review visit prior to the recruitment.
After giving their consent to participate in the study,
a convenience sample of 92 patients was selected by
Table 1 Background characteristics of participants at baseline
Participants
%




Symptoms Occurrence (n = 77)
Less than or 2 days in a week 71.4




Night-time Awakenings (n = 77)
Less than two times in a month 67.5
Three to four times in a month 15.6
More than once in a week, but
not every night
16.9
Use of Reliever Medications for
Control (n = 77)
Less than or 2 days in a week 58.4




Adherence to Prescribed Preventer
Medications (n = 69)
Regular usage 56.5
Irregular usage 43.5
Adverse Drug Events Reported (n = 77)
Yes 42.9
No 57.1
Reported Adverse Events with
Preventer Medications (n = 69)
Regular Preventer Medicine Usage
with Adverse Events
48.7
Regular Preventer Medicine Usage
with No Adverse Events
51.3
Irregular Preventer Medicine Usage
with Adverse Events
40.0
Irregular Preventer Medicine Usage with No Adverse
Events
60.0
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selecting 10 patients out of a mean attendance of 30
patients per week from 4 hospitals for a period of
12 weeks. These participants were administered with
the baseline questionnaires and provided educational
intervention. These participants were followed up one
month after the interventions. Fifteen (15) partici-
pants were lost to follow up. They did not show up
for the post-intervention assessments. Therefore data
for a total number of 77 patients from the baseline
intervention were used for analysis.
Two clinical pharmacists, who were trained for the
study, undertook the patient assessment and provided
educational intervention. The HRQoL instrument was
self-administered by participants. All other participant
data was collected with the “Model Pharmaceutical
Care” forms. The best of 3 PEFR assessments were en-
tered for each participant. The total score for inhaler-use
technique was collated for each participant. Inhaler-use
technique score was the sum of one (1) point per each
correct step undertaken by participant and observed by
the study pharmacist. The maximum total of 7-points
score marks were based on the extension of the manu-
facturers’ inhalation steps as found in product leaflets.
Based on their inhaler-use technique scores, participants
were coached to perform all the steps correctly. The
“Model Pharmaceutical Care” forms were used to
administer questionnaire on “perceived” environmental
trigger factors on individual participant’s asthma and ad-
verse effects from their prescribed medications. The im-
pact of asthma with regards to airway narrowing and the
roles of “reliever” and “preventer” medicines on the air-
ways were explained to each participant. Participant’s
knowledge, PEFR and HRQoL were consecutively re-
assessed in one month after the provision of the
interventions.
Data analysis
Data from the study were subjected to both descriptive
and inferential statistical analysis. Data were analyzed to
generate various tables and charts to demonstrate simi-
lar themes, frequencies, trends and number counts
under the following themes:
 Baseline Characteristics of Asthma Out-patient
Clinic Participants
 Comparison of Asthmatic Patients’ Characteristics
Post Pharmaceutical Care Intervention
Data collected demonstrated normal distribution with
same values for central tendency. Data were therefore
analyzed to test the study hypothesis using a paired
Table 2 Incidence of adverse events reported by participants
Adverse Events Number of
Participants
Adverse Events Number of
Participants
Coughs 8 Headache 2
Dry Mouth 6 Palpitations 1
Light Headedness 3 Sweating 1
Chest Burns 3 Phlegm 1
Sore Throat 3 Nasal Congestion 1
Itching 3 Blurred Vision 1
Sneeze 2 Pins & Needles 1
Nausea 2 Neck Pains 1
Table 3 Participant asthma medication profile




Salbutamol Only 5 (6.5) -
Salbutamol + beclomethasone 1 (1.3) -
Salbutamol + pulmicort 8 (10.4) 1
Salbutamol + budesonide/formoterol 37 (48.1) 2
Salbutamol + fluticasone/salmeterol 22 (28.6) 3
Budesonide/Formoterol only 2 (2.6) -
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samples t-test; the mean differences in the baseline and
post pharmaceutical care intervention HRQoL were
analyzed.
Results
General background characteristics at baseline
Study participants were predominantly female (61%) and
had a mean age of 46 (±15) years. The mean peak expira-
tory flow rate was 284(±103) for the 77 participants. Most
participants in the study had a minimum of high school
education (97.5%) as in Table 1. The daily symptoms oc-
currence (11.7%) and the night-times awakenings (16.9%)
frequencies were similar to reliever medication usage rates
(18.2%), however there was a high irregular use (43.5%) of
preventer medications (Table 1). Many participants
(42.9%) reported one form or the other of various adverse
events perceived to be associated to their asthma
medicines.
Incidence of adverse events
Participants reported of widespread incidence of adverse
drug events perceived to by associated with their asthma
medications. Coughs and dry mouth were the most fre-
quently reported incidence of events (Table 2).
Participants’ inhaler medication profile
Almost all participants (96%) used Salbutamol inhalers.
In addition, Budesonide/formoterol (51%) and Flutica-
sone/salmeterol (31%) inhalers were used in various
combinations (Table 3).
Table 4 presents the number of years participants had
used various inhaler types. While 42% of participants
had used “Reliever” inhalers for 10 years or more, only
4% of participants had used “Preventer” inhaler for that
long. However, 55% of participants had used a “Pre-
venter” for a minimum of one year. Some 6 participants
on “Reliever” inhalers and 7 other participants on “Pre-
venter” inhalers could not recollect for how long they
had used these medicines.
Participants’ inhaler-use technique
Baseline inhaler-use technique score captured using an
inhaler-use technique assessment questionnaire, shown in
Table 5 indicate that only 12% and 17% of participants on
dry powder inhalers (DPI) and metered dose inhalers
(MDI) respectively scored the maximum score of 7 points.
The mean inhaler-use technique scores were 4.66 (1.3) for
the use of DPIs and 5.03(1.43) for the use MDIs.
Environmental trigger-factors affecting participants
Dust (78%), perfume/and strong scents (78%) and smoke
(70%) were the most commonly mentioned environmental
trigger-factors that worsened the asthma of participants
(Table 6). Other trigger-factors like room air-conditioning,
fresh cut grass, and alcohol and beer intake affected about
5% of participants.
Post-pharmaceutical care comparison of participant
characteristics
The quantum of change in HRQoL is displayed in
Table 7. About 56% of participants had a positive change
in HRQoL, while 9% had a negative change after the
pharmaceutical care intervention. However, about 35%
of participants had changes that were not significant.
From Table 8, the paired mean difference values for the
HRQoL and all the domains were above 0.5, the mean im-
portant difference. The overall paired mean difference for
the HRQoL at 95% CI was 0.697 (0.490-0.900) at 95% CI,
with a T- value of 6.845 (2-tailed p < 0.001). The paired
mean difference at 95% CI was highest for the Symptoms
domain 1.134 (0.910 – 1.360) and lowest for the Activity
Limitation domain 0.548 (0.340 - 0.760).
The mean (PEFR) at baseline was 266.5 L/min (SD
85.9), which increased to 284.0 L/min (SD 103.3) after the
intervention (Table 9). The paired mean difference be-
tween baseline and post-pharmaceutical care intervention
PEFR was 17.5 L/min. (95% CI: 2.876-32.190, p < 0.05).






Reliever (%) Preventer (%)
≥10 years 31 (42.3) 3 (3.9)
6 –9 years 8 (10.4) 7 (9.1)
1-5 years 27 (35.1) 42 (54.5)
≤1 year 5 (6.5) 18 (23.4)
Cannot recollect 6 (7.8) 7 (9.1)
Table 5 Participant inhaler-use technique score
Inhaler-use Technique Score (7-point scale)
Inhaler Type 1 2 3 4 5 6 7 Percentage with
Adequate Technique
Mean Score (SD)
DPIa (n = 66) 0 2 10 23 16 9 8 12.12 4.66(1.3)
MDIb (n = 63) 0 4 3 13 19 13 12 17.46 5.03(1.43)
aPDI dry powder inhaler, bMDI metered dose inhaler
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Discussion
Overall participant Inhaler-use technique assessments
revealed low scores. Over half of participants in this
study had used Salbutamol metered-dose inhaler for
more than 5 years, and yet very few had adequate
inhaler-use technique to either the dry powder type of
inhalers or the metered dose type of inhalers. It is pos-
sible that most of the participants had progressed up the
therapeutic steps to the use of Salbutamol with Budeso-
nide/formoterol or Fluticasone/salmeterol (step 3) as a
result of poor asthma control due to inadequate use of
inhalers. In conformity with third Expert Panel Review
(EPR-3, 2007) and Global Initiative for Asthma (GINA,
2014) recommendations, usually after a 3-month period
of well-controlled asthma there should have been a step
down in therapy, [7, 21] but only 12% of patients were
on ICS inhalers alone as controller medication. Poor
inhaler-use technique and /or poor compliance could be
the reason why patient’s asthma was not stable enough
to be stepped down. The GINA guidelines have suggested
that before increasing pharmacologic therapy, one must
first consider poor inhaler technique, poor adherence and
co-morbidities as targets for intervention [7].
The degree of poor inhaler-use technique identified
among study participants indicates that not enough
consideration has been given to the role of inhaler-
use technique in patient management. It further
suggests that there is insufficient patient education
and counselling at the clinic and at the pharmacy,
and that any education and counselling provided to
the study participants in the past clearly did not ad-
equately impact on their skills, or its impact might
have diminished with time.
The common major environmental trigger-factor af-
fecting participants in this study were exposure to dust,
smoke and perfume or strong scents, which suggests
that another major need for intervention is education on
the improved control of environmental triggers by pa-
tients within their environment.
Previous studies by Mangiapane,and colleagues [18],
using a single cohort design, observed significant changes
in both HRQoL, and PEFR, among others. This study also,
using a single cohort design found significant changes in
the HRQoL and the PEFR. Whilst more than half of the
study participants’ perceived improvements in HRQoL,
9% of them perceived worsened HRQoL and 35% did not
perceived any changes in their HRQoL. Though no factual
reasons could be assigned immediately, issues related to
patient adherence to inhaler medications and the influ-
ence of environmental trigger-factors may have played a
role. However, the deterioration and the non-significant
change in HRQoL might also be explained by the “pheno-
type of asthma theory”. The EPR-3 [8] suggests that very
specific patterns of inflammation exist in some individuals
that require different treatment approaches in addition to
the usual steroid-based anti-inflammatory treatment.
The paired mean difference values for the overall general
HRQoL and its various domains were both clinically and
statistically significant, showing benefit of the pharmaceut-
ical care intervention to the patients in all aspects of their
quality of life. The Symptoms domain had the highest mean
change difference of 1.134 (95% CI: 0.910 - 1.360) and the
Activity Limitation had the lowest of 0.548 (95% CI: 0.340
– 0.760). This is an indication that the various domains
were impacted to different extents within the composite
overall HRQoL. Barbanel and colleagues [13] did not use
the HRQoL as the outcomes measure when they
studied the impact of pharmacists’ intervention on
asthma patients. They used asthma symptoms and ob-
served significant improvements. This study also ob-
served more significant improvements within the
symptoms domain than the other various domains
that constituted the composite HRQoL.
However, Mancuso and colleagues [22] found out that
these favourable results from pharmacy interventions
Table 6 Number of participants affected by environmental
trigger-factors
Trigger-factor type Participants




Perfume /Scent 60 77.92
Smoke 54 70.13
Food / Spices 21 27.27
Weather Changes 19 24.68
Stress / Tiredness/Emotions 14 18.18
Cold Drinks 11 14.29
Others (beer, fresh cutting grass,
alcohol & air-conditioner)
4 5.19
Table 7 Quantum changes in quality of life post-pharmaceutical care
Change Health Related Quality of Life (n = 77)
Quantum −3 −2 −1 0 1 2 3
Range −3.49-(−2.50) −2.49- (−1.50) −1.49- (−0.50) −0.49-0.49 0.50-1.49 1.50-2.49 2.50-3.49
Number of Participants (%) 0 (0.00) 1 (1.30) 6 (7.79) 27 (35.06) 29 (37.66) 12 (15.58) 2 (2.60)
Change rate (%) in HRQoL 7 (9.09) 27(35.06) 43(55.84)
Negative Change No Change Positive Change
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tended to wane with time if follow-ups were not pursued
with participants, as may have been the case with our
patients.
This study observed improvements in participants’
values at the end of the intervention as with their
HRQoL.when PEFR measurements were used as a sec-
ondary measure of asthma control. However, analytical
exploration of the values indicated only a weak positive
correlation between the changes in the overall HRQoL
and PEFR from baseline as a result of the intervention.
Previous studies by [15, 19] among others, also observed
significant improvements in the PEFR within the inter-
vention groups.
PEFR are known to have an a diminished correlation
with the FEV1 in patients with asthma, [23] however the
EPR- 2007 recommends PEFR monitoring, using the pa-
tient’s best peak flow in an asthma action plan [21]. The
weak correlation between the PEFR with the HRQoL
therefore is a reflection of their controversial role in
assessing airway obstruction rather than voluntary effort
and muscular strength of the patient [23].
Outstanding are the economic implications of such
intervention on the cost of asthma management.
Further to any clinical significance of educational
intervention, patients and health insurance schemes
might make savings on asthma-related health care,
cost of medications, hospitalization and emergency
department visits as envisaged by [24–26]. Future
studies may be needed to cost and reflect in
monetary terms the savings from the impact of edu-
cational interventions in asthma.
Limitations to the study
This study has some limitations. First, the duration of the
study did not allow for the participants to be followed-up
further to assess duration of the impact of the intervention
or to ascertain whether the therapies of the participants
with significant improvements in HRQoL were subse-
quently adjusted in the post- intervention months. The
design of this study did not factor duration of impact
of the intervention since asthma is a dynamic condi-
tion that would require continuous re-evaluation and
further education in conformity to the recommenda-
tions of GINA and the EPR. Secondly, the AQLQ
used in the study to assess HRQoL were not trans-
lated into any of the local languages for patients who
may not be able to read and write English and
thereby limited the scope of patient participation. Fur-
thermore the study covered the southern and middle
belts of the country and that may to some extent also
limit the overall generalizability of the findings.
Conclusion
This study identified important challenges with both the
pharmacologic and the non-pharmacologic management of
adult asthma patients. Inadequate inhaler-use skills, wide-
spread occurrence of preventable adverse events and




Mean (SD) Paired Differences T Df Sig. (2-tailed)
Mean (SD) 95% CI of the Difference
Lower Upper
HRQoL Pre- 4.15 (1.132) 0.697 (0.891) 0.490 0.900 6.845 76 0.000
Post- 4.85 (1.271)
Activity Limitation Pre- 4.37 (1.143) 0.548 (0.921) 0.340 0.760 5.256 76 0.000
Post- 4.92 (1.224)
Symptoms Pre- 3.998 (1.086) 1.134 (0.985) 0.911 1.358 10.104 76 0.000
Post- 5.132 (1.304)
Emotional Function Pre- 3.907 (1.453) 0.714 (0.938) 0.501 0.927 6.684 76 0.000
Post- 4.621 (1.583)
Environmental Stimuli Pre- 3.289 (1.562) 0.776 (1.099) 0.526 1.025 6.195 76 0.00
Post- 4.065 (1.685)
Table 9 Paired mean difference statistics of peak expiratory flow rate after intervention
Mean (SD) L/min. Paired Differences T Df Sig. (2-tailed)
Mean (SD) L/
min.
95% CI of the Difference
Lower Upper
Peak Flow Rate Pre- 266.467 (85.857) 17.533 (63.705) 2.876 32.190 2.384 74 0.020
Post- 284.000 (103.294)
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irregular use of preventer medicines were prevalent among
patients. At one month after pharmaceutical care interven-
tion, patients with asthma in a cohort follow-up study
showed significant improvements with regard to asthma-
specific quality of life, peak flow rates and knowledge.
Significance of pharmaceutical services in the hospital
A well-structured pharmaceutical care delivery in the
hospital would contribute to patient knowledge and man-
agement and eventually improve the health-related quality
of life of asthma patients. This study has shown that hos-
pital Pharmacists would need to be properly trained to as-
sess patients with asthma and to provide the needed
education to address their individual challenges associated
with the condition and the management.
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